Immungene Looks East for $9M Series A
By Marie Powers
Thursday, November 7, 2013
Immungene Inc. landed a $9 million Series A round from Ally Bridge Group, a health care investment firm with offices in Hong Kong and the U.S., to advance its antibody-cytokine fusion technology platform targeting cancer therapies.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.